Nanoparticle delivery system

• US 7,195,780 B2
• Filed: 10/21/2002
• Issued: 03/27/2007
• Est. Priority Date: 10/21/2002
• Status: Expired due to Fees

• Current Assignee: Florida Research Foundation, Inc.
• Original Assignee: University of Florida (State University System of Florida)
• Inventors: Stewart, Jon D., Dennis, Donn M., Martin, Charles R., Rogers, Richard J.
• Primary Examiner(s): Azpuru; Carlos A.
• Application Number:
  US10/274,829
• Publication Number:
  US 20040076681A1
• Time in Patent Office: 1,618 Days
• Field of Search: 424/489, 424/501, 424/502
• US Class Current: 424/502
• CPC Class Codes: A61K 47/6849 the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
• CPC Class Codes: A61K 47/6923 the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
• CPC Class Codes: A61K 9/0092 Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• CPC Class Codes: Y10T 428/2984 Microcapsule with fluid core [includes liposome]
• CPC Class Codes: Y10T 428/2987 Addition polymer from unsaturated monomers only

Abstract

The invention relates to the nanotubes of various sizes and composed of a wide variety of materials, or combination of materials. The invention also describes the use of such nanotubes for the delivery of various payloads and, in particular, for the in vivo delivery of bioactive substances.

Claims

1. A nanotube comprising:

(a) a hollow tubular body defining an inner void, comprising a first end and a second end, wherein the first end is open; and

(b) a first end cap positioned over the first open end,

wherein the end cap is attached to the hollow tubular body by a covalent bond and the capped nanotube has a maximum dimension of less than 100 μ

m.

2. The nanotube of claim 1, wherein the second end is open and a second end cap is positioned over the second open end, wherein the second end cap is attached to the hollow tubular body by a covalent bond.

3. The nanotube of claim 1, wherein the second end is closed.

4. The nanotube of claim 1, wherein the maximum dimension of the nanotube is less than 500 nm.

5. The nanotube of claim 4, wherein the diameter of the nanotube is less than 200 nm.

6. The nanotube of claim 5, wherein the maximum dimension of the nanotube is less than 100 nm.

7. The nanotube of claim 1, wherein a diameter of the tubular body is greater than 5 nm.

8. The nanotube of claim 1, wherein the tubular body comprises materials selected from a group consisting of a polymer, a semiconductor, carbon, Li+intercalation materials, and silica.

9. The nanotube of claim 8, wherein the tubular body comprises a polymer.

10. The nanotube of claim 9, wherein the polymer is biodegradable.

11. The nanotube of claim 9, wherein the polymer is biocompatible.

12. The nanotube of claim 10, wherein the polymer is poly(lactic acid).

13. The nanotube of claim 8, wherein a surface of the tubular body is functionalized.

14. The nanotube of claim 13, further comprising a protein attached to the surface.

15. The nanotube of claim 14, wherein the protein is selected from a group consisting of an antibody, an antibody fragment, and a cellular receptor ligand.

16. The nanotube of claim 13, wherein an outer surface of the tubular body is functionalized.

17. The nanotube of claim 1, further comprising a payload, wherein the payload fills the inner void of the tubular body.

18. The nanotube of claim 17, wherein the payload is a bioactive agent.

19. The nanotube of claim 18, wherein the bioactive agent is selected from a group consisting of a nucleic acid, a chemotherapeutic, an immunosuppressant, an antibiotic, an endocrine drug, an antifungal agent, a cardiovascular drug, and a renal drug.

20. The nanotube of claim 1, wherein the covalent bond is a disulfide bond.

21. The nanotube of claim 1, wherein a biocompatible material is attached to an outer surface of the nanotube.

22. The nanotube of claim 21, wherein the biocompatible material is selected from a group consisting of PEGylated PLGA, PLGA, chitosan, and polylactic acid.

23. The nanotube of claim 22, wherein the biocompatible material is PEGylated PLGA.

24. A bioactive agent delivery system comprising:

(a) a hollow tubular body defining an inner void, comprising a first end and a second end, wherein the first end is open;

(b) a first end cap positioned over the first open end, wherein the end cap is attached to the hollow tubular body by a covalent bond;

(c) a bioactive agent,

wherein the bioactive agent is contained within the inner void and the hollow tubular body has a maximum dimension of less than 100 μ

m.

33. The delivery system of claim 24, wherein the bioactive agent is selected from the group consisting of DNA, oligonucleotides, chemotherapeutics, antibiotics, antifungal agents, anesthetics, immunomodulators, anti-inflammatory drugs, pain relieving drugs, autonomic drugs, cardiovascular-renal drugs, endocrine drugs, hematopoietic growth factors, blood lipid lowering drugs, AIDS drugs, modulators of smooth muscle function, antileptics, and psychoactive drugs.

25. A nanotube delivery system comprising:

(a) a hollow tubular body defining an inner void, comprising a first open end and a second open end; and

(b) a bioactive agent attached to a surface of the hollow tubular body by a covalent or non-covalent bond, wherein the hollow tubular body has a maximum dimension of less than 100 μ

m.

26. The delivery system of claim 25, wherein the maximum dimension is less than 500 nm.

27. The delivery system of claim 26, wherein the maximum dimension is less than 100 nm.

28. The delivery system of claim 25, wherein the hollow tubular body comprises materials selected from a group consisting of a polymer, a semiconductor, carbon, Li+intercalation materials, and silica.

29. The delivery system of claim 28, wherein the hollow tubular body comprises a polymer.

30. The delivery system of claim 29, wherein the polymer is biodegradable.

31. The delivery system of claim 29, wherein the polymer is biocompatible.

32. The delivery system of claim 25, wherein the bioactive agent is selected from the group consisting of DNA, oligonucleotides, chemotherapeutics, antibiotics, antifungal agents, anesthetics, immunomodulators, anti-inflammatory drugs, pain relieving drugs, autonomic drugs, cardiovascular-renal drugs, endocrine drugs, hematopoietic growth factors, blood lipid lowering drugs, AIDS drugs, modulators of smooth muscle function, antileptics, and psychoactive drugs.